Gamida Cell (NASDAQ:GMDA) vs. The Competition Head-To-Head Comparison

Gamida Cell (NASDAQ: GMDA) is one of 114 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its rivals? We will compare Gamida Cell to similar companies based on the strength of its valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Valuation & Earnings

This table compares Gamida Cell and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Gamida Cell N/A -$52.93 million -0.80
Gamida Cell Competitors $897.64 million $190.37 million -1.20

Gamida Cell’s rivals have higher revenue and earnings than Gamida Cell. Gamida Cell is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Gamida Cell and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gamida Cell N/A N/A N/A
Gamida Cell Competitors -5,144.22% -64.24% -27.96%

Insider & Institutional Ownership

1.8% of Gamida Cell shares are owned by institutional investors. Comparatively, 48.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 16.4% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Gamida Cell and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gamida Cell 0 0 5 0 3.00
Gamida Cell Competitors 837 2782 6074 261 2.58

Gamida Cell presently has a consensus price target of $19.40, suggesting a potential upside of 130.68%. As a group, “Biological products, except diagnostic” companies have a potential upside of 40.51%. Given Gamida Cell’s stronger consensus rating and higher probable upside, analysts plainly believe Gamida Cell is more favorable than its rivals.

Summary

Gamida Cell beats its rivals on 7 of the 12 factors compared.

About Gamida Cell

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.